PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

6.35%

29.5¢

Market Cap $117.2M

Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug... Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.More

Corporate Spotlight

Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs.
View the full Corporate Spotlight

PAR - close to a cure for osteoarthritis?

Announcements

Filter Results

All Price Sensitive Only

PAR	Cleansing Notice and Appendix 3B		24/09/19	397.03KB	Share
PAR	Cleansing Notice and Appendix 3B		17/09/19	1.01MB	Share
PAR	Cleansing Notice and Appendix 3B		12/09/19	396.59KB	Share
PAR	PAR Expanded Access IND Cleared by US FDA	PRICE SENSITIVE	10/09/19	232.16KB	Share
PAR	Appendix 4G and 2019 Corporate Governance Statement		30/08/19	403.85KB	Share
PAR	Appendix 4E and 2019 Annual Report	PRICE SENSITIVE	30/08/19	1.12MB	Share
PAR	PARs drug reduces cartilage degradation in subjects with OA	PRICE SENSITIVE	29/08/19	1.19MB	Share
PAR	PARADIGM FILES FIRST IND WITH US FDA	PRICE SENSITIVE	07/08/19	146.39KB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	134.51KB	Share
PAR	Response to ASX Appendix 3Y Query		05/07/19	522.29KB	Share
PAR	Change of Director's Interest Notice		03/07/19	176.53KB	Share
PAR	Change in substantial holding		02/07/19	382.01KB	Share
PAR	Change of Director's Interest Notice		02/07/19	430.5KB	Share
PAR	Paradigm EOFY Update	PRICE SENSITIVE	28/06/19	326.67KB	Share
PAR	PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL	PRICE SENSITIVE	04/06/19	408.29KB	Share
PAR	PAR reports consistent pain reduction in knee OA of patients	PRICE SENSITIVE	28/05/19	352.81KB	Share
PAR	PAR CORRECTS AFR ARTICLE	PRICE SENSITIVE	21/05/19	83.76KB	Share
PAR	Updated Appendix 3B		13/05/19	428.13KB	Share
PAR	Appendix 3B		13/05/19	425.63KB	Share
PAR	Successful Completion of Retail Entitlement Offer	PRICE SENSITIVE	09/05/19	142.58KB	Share
PAR	Paradigm Corporate Update - May 2019	PRICE SENSITIVE	08/05/19	301.29KB	Share
PAR	Quarterly Report and Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	1.22MB	Share
PAR	Appendix 3B		26/04/19	279.04KB	Share
PAR	Cleansing Notice under section708A		26/04/19	404.13KB	Share
PAR	Completion of Institutional Entitlement Offer	PRICE SENSITIVE	24/04/19	161.84KB	Share
PAR	Cleansing statement under Section 708AA		24/04/19	156.1KB	Share
PAR	Change of Director's Interest Notice		23/04/19	474.6KB	Share
PAR	PAR Accelerated Non-Renounceable Rights Issue Offer Booklet	PRICE SENSITIVE	17/04/19	589.83KB	Share
PAR	Paradigm Confirms Capital Raise Commitments	PRICE SENSITIVE	17/04/19	104.96KB	Share
PAR	PARADIGM UPDATED CORPORATE PRESENTATION	PRICE SENSITIVE	15/04/19	1.93MB	Share
PAR	Appendix 3B		15/04/19	762.82KB	Share
PAR	PARADIGM LAUNCHES A$77.9M CAPITAL RAISE	PRICE SENSITIVE	15/04/19	100.11KB	Share
PAR	Cleansing statement under Section 708AA		15/04/19	223.23KB	Share
PAR	Trading Halt	PRICE SENSITIVE	15/04/19	463.2KB	Share
PAR	PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET	PRICE SENSITIVE	15/04/19	4.01MB	Share
PAR	Trading Halt	PRICE SENSITIVE	11/04/19	511.1KB	Share
PAR	Response to ASX Price Query	PRICE SENSITIVE	28/03/19	675.46KB	Share
PAR	Paradigm (PAR) Updated Investor Presentation	PRICE SENSITIVE	13/03/19	19.1MB	Share
PAR	Change of Director's Interest Notice		08/03/19	473.03KB	Share
PAR	S&P DJI Announces March 2019 Quarterly Rebalance	PRICE SENSITIVE	08/03/19	175.31KB	Share
PAR	Half Yearly Report and Accounts	PRICE SENSITIVE	21/02/19	384.01KB	Share
PAR	Cleansing Notice and Appendix 3B		14/02/19	953.72KB	Share
PAR	PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES	PRICE SENSITIVE	14/02/19	1.85MB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	423.18KB	Share
PAR	PARADIGMS SUPPLEMENTARY PHASE 2B DATA	PRICE SENSITIVE	20/12/18	812.37KB	Share
PAR	PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS	PRICE SENSITIVE	18/12/18	3.09MB	Share
PAR	PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL	PRICE SENSITIVE	18/12/18	576.83KB	Share
PAR	PAR - Conference Call Details - Phase 2b OA Results		17/12/18	176.21KB	Share
PAR	Trading Halt	PRICE SENSITIVE	14/12/18	505.17KB	Share
PAR	Change in substantial holding		13/12/18	154.21KB	Share
PAR	Change of Director's Interest Notice		13/12/18	430.61KB	Share
PAR	Appendix 3B and Cleansing Notice		13/12/18	952.71KB	Share
PAR	PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION	PRICE SENSITIVE	07/12/18	140.04KB	Share
PAR	Cleansing Notice and Appendix 3B		30/11/18	953.33KB	Share
PAR	Cleansing Notice and Appendix 3B		27/11/18	954.06KB	Share
PAR	Results of Meeting		26/11/18	118.78KB	Share
PAR	Paradigm's AGM Presentation	PRICE SENSITIVE	26/11/18	1.13MB	Share
PAR	Paradigm in-licenses treatment for rare joint disease	PRICE SENSITIVE	22/11/18	115.87KB	Share
PAR	PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND	PRICE SENSITIVE	15/11/18	277.14KB	Share
PAR	PAR reports pain reduction in 145 people with osteoarthritis	PRICE SENSITIVE	07/11/18	333.11KB	Share
PAR	Cleansing Notice and Appendix 3B		01/11/18	954.01KB	Share
PAR	Quarterly Report and Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	376.54KB	Share
PAR	Notice of Annual General Meeting/Proxy Form		26/10/18	510.97KB	Share
PAR	Paradigm Agreement With USA Past Players Network	PRICE SENSITIVE	25/10/18	357.94KB	Share
PAR	Paradigm's Updated Corporate Presentation	PRICE SENSITIVE	25/10/18	1.62MB	Share
PAR	Paradigm Raises A$9 Million	PRICE SENSITIVE	25/10/18	368.92KB	Share
PAR	Trading Halt	PRICE SENSITIVE	23/10/18	442.11KB	Share
PAR	PAR REPORTS PAIN REDUCTION IN OA PATIENTS	PRICE SENSITIVE	25/09/18	467.25KB	Share
PAR	Phase2a RossRiver Virus Clinical Trial Recruitment Finalised	PRICE SENSITIVE	28/08/18	258.57KB	Share
PAR	Appendix 4G and Corporate Governance Statement		24/08/18	157.27KB	Share
PAR	Appendix 4E and 2018 Annual Report	PRICE SENSITIVE	24/08/18	582.45KB	Share
PAR	PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN	PRICE SENSITIVE	15/08/18	334.37KB	Share
PAR	Cleansing Notice and Appendix 3B		08/08/18	964.42KB	Share
PAR	PAR achieves 100 per cent recruitment in Phase 2b OA Trial	PRICE SENSITIVE	06/08/18	334.6KB	Share
PAR	Quarterly Report and Appendix 4C - quarterly	PRICE SENSITIVE	27/07/18	508.08KB	Share
PAR	Cleansing Notice and Appendix 3B		27/07/18	959.29KB	Share
PAR	Cleansing Notice and Appendix 3B		17/07/18	835.26KB	Share
PAR	Response to ASX Price Query	PRICE SENSITIVE	09/07/18	436.31KB	Share
PAR	Cleansing Notice and Appendix 3B		04/07/18	1008.52KB	Share
PAR	Cleansing Notice and Appendix 3B		26/06/18	836.38KB	Share
PAR	Appendix 3B and Cleansing Notice		19/06/18	836.47KB	Share
PAR	PAR - 50% REDUCTION IN OSTEOARTHRITIS PAIN MAINTAINED	PRICE SENSITIVE	15/06/18	127.93KB	Share
PAR	Cleansing Notice		18/05/18	325.57KB	Share
PAR	Appendix 3B		18/05/18	147.62KB	Share
PAR	Paradigm OA Phase 2b Clinical Trial over 80% Recruited	PRICE SENSITIVE	17/05/18	526.54KB	Share
PAR	Change of Director's Interest Notice		08/05/18	232KB	Share
PAR	Cleansing Notice		08/05/18	325.45KB	Share
PAR	Appendix 3B		07/05/18	369.54KB	Share
PAR	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/18	437.29KB	Share
PAR	PAR Non-Deal Roadshow Presentation		17/04/18	1.36MB	Share
PAR	Corporate Governance Statement		13/04/18	322.65KB	Share
PAR	PARADIGMs PHASE 2 CLINICAL DATA UPDATE	PRICE SENSITIVE	27/03/18	378.51KB	Share
PAR	PARADIGM REPORTS OSTEOARTHRITIS PAIN REDUCED BY 50%	PRICE SENSITIVE	01/03/18	514.22KB	Share
PAR	Half Year Accounts	PRICE SENSITIVE	22/02/18	1.1MB	Share
PAR	Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/01/18	292.88KB	Share
PAR	Elite sportspeople successfully treated with PPS		24/01/18	462.48KB	Share
PAR	PARs European Patent Granted for Bone Marrow Edema Lesions	PRICE SENSITIVE	16/01/18	453.54KB	Share
PAR	Paradigm Shareholder Newsletter		20/12/17	1.3MB	Share
PAR	Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule	PRICE SENSITIVE	23/11/17	281.76KB	Share
PAR	Appendix 3B and Cleansing Notice		16/11/17	835.91KB	Share

PAR Cleansing Notice and Appendix 3B
24/09/19		397.03KB	Share
PAR Cleansing Notice and Appendix 3B
17/09/19		1.01MB	Share
PAR Cleansing Notice and Appendix 3B
12/09/19		396.59KB	Share
PAR PAR Expanded Access IND Cleared by US FDA
10/09/19	PRICE SENSITIVE	232.16KB	Share
PAR Appendix 4G and 2019 Corporate Governance Statement
30/08/19		403.85KB	Share
PAR Appendix 4E and 2019 Annual Report
30/08/19	PRICE SENSITIVE	1.12MB	Share
PAR PARs drug reduces cartilage degradation in subjects with OA
29/08/19	PRICE SENSITIVE	1.19MB	Share
PAR PARADIGM FILES FIRST IND WITH US FDA
07/08/19	PRICE SENSITIVE	146.39KB	Share
PAR Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	134.51KB	Share
PAR Response to ASX Appendix 3Y Query
05/07/19		522.29KB	Share
PAR Change of Director's Interest Notice
03/07/19		176.53KB	Share
PAR Change in substantial holding
02/07/19		382.01KB	Share
PAR Change of Director's Interest Notice
02/07/19		430.5KB	Share
PAR Paradigm EOFY Update
28/06/19	PRICE SENSITIVE	326.67KB	Share
PAR PAR REPORTS SUCCESSFUL ROSS RIVER PHASE 2 CLINICAL TRIAL
04/06/19	PRICE SENSITIVE	408.29KB	Share
PAR PAR reports consistent pain reduction in knee OA of patients
28/05/19	PRICE SENSITIVE	352.81KB	Share
PAR PAR CORRECTS AFR ARTICLE
21/05/19	PRICE SENSITIVE	83.76KB	Share
PAR Updated Appendix 3B
13/05/19		428.13KB	Share
PAR Appendix 3B
13/05/19		425.63KB	Share
PAR Successful Completion of Retail Entitlement Offer
09/05/19	PRICE SENSITIVE	142.58KB	Share
PAR Paradigm Corporate Update - May 2019
08/05/19	PRICE SENSITIVE	301.29KB	Share
PAR Quarterly Report and Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	1.22MB	Share
PAR Appendix 3B
26/04/19		279.04KB	Share
PAR Cleansing Notice under section708A
26/04/19		404.13KB	Share
PAR Completion of Institutional Entitlement Offer
24/04/19	PRICE SENSITIVE	161.84KB	Share
PAR Cleansing statement under Section 708AA
24/04/19		156.1KB	Share
PAR Change of Director's Interest Notice
23/04/19		474.6KB	Share
PAR PAR Accelerated Non-Renounceable Rights Issue Offer Booklet
17/04/19	PRICE SENSITIVE	589.83KB	Share
PAR Paradigm Confirms Capital Raise Commitments
17/04/19	PRICE SENSITIVE	104.96KB	Share
PAR PARADIGM UPDATED CORPORATE PRESENTATION
15/04/19	PRICE SENSITIVE	1.93MB	Share
PAR Appendix 3B
15/04/19		762.82KB	Share
PAR PARADIGM LAUNCHES A$77.9M CAPITAL RAISE
15/04/19	PRICE SENSITIVE	100.11KB	Share
PAR Cleansing statement under Section 708AA
15/04/19		223.23KB	Share
PAR Trading Halt
15/04/19	PRICE SENSITIVE	463.2KB	Share
PAR PARADIGMS SECONDARY ENDPOINTS SUCCESSFULLY MET
15/04/19	PRICE SENSITIVE	4.01MB	Share
PAR Trading Halt
11/04/19	PRICE SENSITIVE	511.1KB	Share
PAR Response to ASX Price Query
28/03/19	PRICE SENSITIVE	675.46KB	Share
PAR Paradigm (PAR) Updated Investor Presentation
13/03/19	PRICE SENSITIVE	19.1MB	Share
PAR Change of Director's Interest Notice
08/03/19		473.03KB	Share
PAR S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19	PRICE SENSITIVE	175.31KB	Share
PAR Half Yearly Report and Accounts
21/02/19	PRICE SENSITIVE	384.01KB	Share
PAR Cleansing Notice and Appendix 3B
14/02/19		953.72KB	Share
PAR PARADIGMS ORPHAN PHASE 2/3 CLINICAL PROGRAM PROGRESSES
14/02/19	PRICE SENSITIVE	1.85MB	Share
PAR Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	423.18KB	Share
PAR PARADIGMS SUPPLEMENTARY PHASE 2B DATA
20/12/18	PRICE SENSITIVE	812.37KB	Share
PAR PRESENTATION OF PHASE 2 CLINICAL TRIAL RESULTS
18/12/18	PRICE SENSITIVE	3.09MB	Share
PAR PAR REPORTS SUCCESSFUL PHASE 2 CLINICAL TRIAL
18/12/18	PRICE SENSITIVE	576.83KB	Share
PAR PAR - Conference Call Details - Phase 2b OA Results
17/12/18		176.21KB	Share
PAR Trading Halt
14/12/18	PRICE SENSITIVE	505.17KB	Share
PAR Change in substantial holding
13/12/18		154.21KB	Share
PAR Change of Director's Interest Notice
13/12/18		430.61KB	Share
PAR Appendix 3B and Cleansing Notice
13/12/18		952.71KB	Share
PAR PARADIGM REPORTS CONSISTENT OA PAIN REDUCTION
07/12/18	PRICE SENSITIVE	140.04KB	Share
PAR Cleansing Notice and Appendix 3B
30/11/18		953.33KB	Share
PAR Cleansing Notice and Appendix 3B
27/11/18		954.06KB	Share
PAR Results of Meeting
26/11/18		118.78KB	Share
PAR Paradigm's AGM Presentation
26/11/18	PRICE SENSITIVE	1.13MB	Share
PAR Paradigm in-licenses treatment for rare joint disease
22/11/18	PRICE SENSITIVE	115.87KB	Share
PAR PARADIGM RECEIVES $2.32m R&D TAX INCENTIVE REFUND
15/11/18	PRICE SENSITIVE	277.14KB	Share
PAR PAR reports pain reduction in 145 people with osteoarthritis
07/11/18	PRICE SENSITIVE	333.11KB	Share
PAR Cleansing Notice and Appendix 3B
01/11/18		954.01KB	Share
PAR Quarterly Report and Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	376.54KB	Share
PAR Notice of Annual General Meeting/Proxy Form
26/10/18		510.97KB	Share
PAR Paradigm Agreement With USA Past Players Network
25/10/18	PRICE SENSITIVE	357.94KB	Share
PAR Paradigm's Updated Corporate Presentation
25/10/18	PRICE SENSITIVE	1.62MB	Share
PAR Paradigm Raises A$9 Million
25/10/18	PRICE SENSITIVE	368.92KB	Share
PAR Trading Halt
23/10/18	PRICE SENSITIVE	442.11KB	Share
PAR PAR REPORTS PAIN REDUCTION IN OA PATIENTS
25/09/18	PRICE SENSITIVE	467.25KB	Share
PAR Phase2a RossRiver Virus Clinical Trial Recruitment Finalised
28/08/18	PRICE SENSITIVE	258.57KB	Share
PAR Appendix 4G and Corporate Governance Statement
24/08/18		157.27KB	Share
PAR Appendix 4E and 2018 Annual Report
24/08/18	PRICE SENSITIVE	582.45KB	Share
PAR PAR ACHIEVES 60 PER CENT REDUCTION IN OSTEOARTHRITIS PAIN
15/08/18	PRICE SENSITIVE	334.37KB	Share
PAR Cleansing Notice and Appendix 3B
08/08/18		964.42KB	Share
PAR PAR achieves 100 per cent recruitment in Phase 2b OA Trial
06/08/18	PRICE SENSITIVE	334.6KB	Share
PAR Quarterly Report and Appendix 4C - quarterly
27/07/18	PRICE SENSITIVE	508.08KB	Share
PAR Cleansing Notice and Appendix 3B
27/07/18		959.29KB	Share
PAR Cleansing Notice and Appendix 3B
17/07/18		835.26KB	Share
PAR Response to ASX Price Query
09/07/18	PRICE SENSITIVE	436.31KB	Share
PAR Cleansing Notice and Appendix 3B
04/07/18		1008.52KB	Share
PAR Cleansing Notice and Appendix 3B
26/06/18		836.38KB	Share
PAR Appendix 3B and Cleansing Notice
19/06/18		836.47KB	Share
PAR PAR - 50% REDUCTION IN OSTEOARTHRITIS PAIN MAINTAINED
15/06/18	PRICE SENSITIVE	127.93KB	Share
PAR Cleansing Notice
18/05/18		325.57KB	Share
PAR Appendix 3B
18/05/18		147.62KB	Share
PAR Paradigm OA Phase 2b Clinical Trial over 80% Recruited
17/05/18	PRICE SENSITIVE	526.54KB	Share
PAR Change of Director's Interest Notice
08/05/18		232KB	Share
PAR Cleansing Notice
08/05/18		325.45KB	Share
PAR Appendix 3B
07/05/18		369.54KB	Share
PAR Appendix 4C - quarterly
30/04/18	PRICE SENSITIVE	437.29KB	Share
PAR PAR Non-Deal Roadshow Presentation
17/04/18		1.36MB	Share
PAR Corporate Governance Statement
13/04/18		322.65KB	Share
PAR PARADIGMs PHASE 2 CLINICAL DATA UPDATE
27/03/18	PRICE SENSITIVE	378.51KB	Share
PAR PARADIGM REPORTS OSTEOARTHRITIS PAIN REDUCED BY 50%
01/03/18	PRICE SENSITIVE	514.22KB	Share
PAR Half Year Accounts
22/02/18	PRICE SENSITIVE	1.1MB	Share
PAR Quarterly Update and Appendix 4C
30/01/18	PRICE SENSITIVE	292.88KB	Share
PAR Elite sportspeople successfully treated with PPS
24/01/18		462.48KB	Share
PAR PARs European Patent Granted for Bone Marrow Edema Lesions
16/01/18	PRICE SENSITIVE	453.54KB	Share
PAR Paradigm Shareholder Newsletter
20/12/17		1.3MB	Share
PAR Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
23/11/17	PRICE SENSITIVE	281.76KB	Share
PAR Appendix 3B and Cleansing Notice
16/11/17		835.91KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 29.5¢		Change -0.020(6.35%)		Mkt cap ! $117.2M

Open	High	Low	Value	Volume
30.5¢	31.3¢	29.5¢	$188.4K	621.3K

Buyers (Bids)

No.	Vol.	Price($)
8	102652	29.5¢

Sellers (Offers)

Price($)	Vol.	No.
31.0¢	200000	1

View Market Depth

No.	Vol.	Price($)
8	102652	0.295
11	260742	0.290
9	1055356	0.285
5	58071	0.280
1	740	0.270

Price($)	Vol.	No.
0.310	200000	1
0.315	6795	3
0.320	27519	4
0.335	15000	1
0.340	60000	2

Last trade - 16.10pm 12/08/2025 (20 minute delay)

PAR (ASX) Chart

PARADIGM BIOPHARMACEUTICALS LIMITED.. - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories